Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
13.77 USD +1.85% Intraday chart for Tourmaline Bio, Inc. +2.38% -47.40%
May. 16 Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial CI
May. 13 Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Tourmaline Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

36b403de8c55fc2af5.kWmTNYj993DVdJgfuhuZ21V3-xrpYxO4SUV6zckMYhM.xy7efrGJpzGFHc5R0VrqiWc4vkiBAl3COQcwm7N7PV3YEfdD6pPFNrsQ6w~269da8d6307b9bfc2657961064084fcf

Analyst Recommendations on Tourmaline Bio, Inc.

Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target MT
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target MT
Piper Sandler Initiates Coverage on Tourmaline Bio with Overweight Rating, $65 Price Target MT
HC Wainwright Downgrades Talaris Therapeutics to Neutral From Buy MT
Morgan Stanley Adjusts Price Target on Talaris Therapeutics to $3 From $6, Keeps Equalweight Rating MT
HC Wainwright Adjusts Talaris Therapeutics' Price Target to $12 From $18, Maintains Buy Rating MT
SVB Securities Lowers Talaris Therapeutics Price Target to $2 From $7, Maintains Market Perform Rating MT
HC Wainwright Starts Talaris Therapeutics at Buy With $18 Price Target MT
Morgan Stanley Cuts Price Target on Talaris Therapeutics to $6 From $8, Maintains Equalweight Rating MT
Morgan Stanley Downgrades Talaris Therapeutics to Equalweight From Overweight; Price Target is $8 MT
SVB Securities Downgrades Talaris Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $21 MT
Morgan Stanley Adjusts Talaris Therapeutics' Price Target to $20 from $21, Keeps Overweight Rating MT
Morgan Stanley Adjusts Talaris Therapeutics Price Target to $21 From $20, Maintains Overweight Rating MT
TALARIS THERAPEUTICS : SVB Leerink Starts Talaris Therapeutics at Outperform With $21 Price Target MT
TALARIS THERAPEUTICS : Evercore ISI Starts Talaris Therapeutics at Outperform With $35 Price Target MT
TALARIS THERAPEUTICS : Morgan Stanley Starts Talaris Therapeutics at Overweight With $35 Price Target MT
TALARIS THERAPEUTICS : Guggenheim Starts Talaris Therapeutics at Buy With $26 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.77 USD
Average target price
58.33 USD
Spread / Average Target
+323.63%
High Price Target
74 USD
Spread / Highest target
+437.40%
Low Price Target
48 USD
Spread / Lowest Target
+248.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tourmaline Bio, Inc.

Jefferies & Co.
Truist Securities
Piper Sandler
HC Wainwright
Morgan Stanley
SVB Securities LLC
SVB Leerink
Evercore ISI
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRML Stock
  4. Consensus Tourmaline Bio, Inc.